Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,010.60 +43.37 (+0.87%) Dow
38,239.98 +253.58 (+0.67%) Nasdaq
15,451.31 +169.30 (+1.11%) Bitcoin USD
66,141.08 +183.29 (+0.28%) CMC Crypto 200
1,418.84 +4.08 (+0.29%)
Novartis AG (NVS)
Pre-market:
| Previous close | 94.36 |
| Open | 94.76 |
| Bid | 0.00 x 900 |
| Ask | 99.98 x 900 |
| Day's range | 94.72 - 96.03 |
| 52-week range | 92.19 - 108.78 |
| Volume | |
| Avg. volume | 1,536,366 |
| Market cap | 195.984B |
| Beta (5Y monthly) | 0.47 |
| PE ratio (TTM) | 23.20 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 3.78 (3.97%) |
| Ex-dividend date | 07 Mar 2024 |
| 1y target est | N/A |
- GlobeNewswire
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
Ad hoc announcement pursuant to Art. 53 LRQ1 net sales grew +11% (cc1, +10% USD) with core operating income up +22% (cc, +16% USD) Key growth drivers continued strong sales momentum including Entresto (+36% cc), Cosentyx (+25% cc), Kesimpta (+66% cc), Kisqali (+54% cc), Pluvicto (+47% cc) and Leqvio (+139% cc)Core operating income margin 38.4%, +340 basis points (cc), mainly driven by higher net salesOperating income grew +39% (cc, +29% USD) and net income grew +37% (cc, +25% USD), mainly driven
- GlobeNewswire
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
Continuous Kesimpta® treatment for up to six years showed sustained efficacy in recently diagnosed (≤3 years) treatment-naïve people living with relapsing multiple sclerosis (RMS) in an analysis of the ALITHIOS open-label extension study1Similar efficacy outcomes were demonstrated in a separate analysis of continuous Kesimpta treatment for up to six years in the overall ALITHIOS study population2 Switch from teriflunomide to Kesimpta resulted in significant improvements across several efficacy o
- GlobeNewswire
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
APPLAUSE-IgAN is first and only Phase III study to demonstrate significant proteinuria reduction by targeting the complement system in patients with IgAN1IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide2; complement activation is a key driver of glomerular inflammation in IgAN3,4There is a need for effective, targeted therapies for IgAN2,5; up to 30% of patients with persistent proteinuria (≥1 g/day) may progress to kidney failure
